News
FDA looks at Opdivo/Yervoy in first-line colorectal cancer
The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for MSI-H/dMMR colorectal cancer.
Saturday 3 May 2025
